C. Teruel

发表

Outcomes of Pregnancies Fathered by Inflammatory Bowel Disease Patients Exposed to Thiopurines

J. Gisbert, A. Muriel, C. Taxonera, 2010, The American Journal of Gastroenterology.

A topological-substructural molecular design (TOPS-MODE) approach to determining pharmacokinetics and pharmacological properties of 6-fluoroquinolone derivatives.

M. A. Cabrera Pérez, C. Teruel, M. B. Sanz, 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Gastroesophageal reflux as a cause of chronic cough, severe asthma, and migratory pulmonary infiltrates

I. Cobeta, C. Teruel, P. Ribó, 2013, Respirology case reports.

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

M. Ratain, J. Tabernero, C. Kahatt, 2014, Clinical Cancer Research.

Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis

N. Garin, C. Teruel, C. Domingo, 2022, Applied Health Economics and Health Policy.

Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.

F. Mesonero, C. Teruel, E. Garrido, 2016, World journal of gastrointestinal pharmacology and therapeutics.

Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

L. Paz-Ares, M. Forster, V. Boni, 2017, Investigational New Drugs.

Small intestine perforation after colonoscopy: rare complication in patients with previous abdominal surgery.

C. Teruel, A. Ledo, J. Graus, 2009, Endoscopy.

Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome

E. Rey, C. Teruel, F. Geijo, 2021, Therapeutic advances in gastroenterology.

A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.

B. Mellado, R. Hauke, T. Morris, 2021, Clinical genitourinary cancer.

Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

C. Suárez, F. Salgado Ordóñez, A. Riera-Mestre, 2021, BMC Cardiovascular Disorders.

Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors

A. Drilon, D. Hyman, A. Stathis, 2016 .

[Susac syndrome: presentation of a new case].

C. Teruel, A. Dávalos, M. Castellanos, 1999, Neurologia.

A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients.

C. Teruel, B. Roca, A. Arnedo, 1998, Scandinavian journal of infectious diseases.

A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.

B. Mellado, R. Hauke, T. Morris, 2022, Clinical genitourinary cancer.